GLYCOMIMETICS INC

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 13, 2025

CBIO$13.65+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets


	December 31,
· 2024 · · 2023
Assets · · · · · ·
Current assets:
Cash and cash equivalents		$10,720,178	$41,792,830
Prepaid expenses and other current assets		371,276	1,997,904
Total current assets		11,091,454	43,790,734
Prepaid research and development expenses		—	603,737
Operating lease right-of-use asset		—	767,828
Other assets		—	154,176
Total assets		$11,091,454	$45,316,475
Liabilities & stockholders’ equity
Current liabilities:
Accounts payable		$329,304	$868,115
Accrued expenses		5,381,744	5,225,557
Lease liabilities		66,844	741,558
Total current liabilities		5,777,892	6,835,230
Lease liabilities, net of current portion		—	66,844
Total liabilities		5,777,892	6,902,074
Stockholders’ equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023		—	—
Common stock; $0.001 par value; 150,000,000 shares authorized at December 31, 2024; 100,000,000 shares authorized at December 31, 2023; 64,483,958 shares issued and outstanding at December 31, 2024; 64,393,744 shares issued and outstanding at December 31, 2023		64,484	64,394
Additional paid-in capital		499,613,448	494,835,219
Accumulated deficit		(494,364,370)	(456,485,212)
Total stockholders’ equity		5,313,562	38,414,401
Total liabilities and stockholders’ equity		$11,091,454	$45,316,475

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.